Second, the radiotracer used in the EMPIRE-1 trial was 18F-fluciclovine, which has been shown to be less performant than PSMA-PET in detecting prostate cancer. In our study, physicians maintained treatment volumes (eg, pelvis and prostate bed) even without PSMA-PET uptake in pelvic nodes because deescalation of radiotherapy was not permitted, unlike in the EMPIRE-1 clinical trial. This evidence concerns the gene FOLH1 and prostate carcinoma.